item management s discussion and analysis of financial condition and results of operations 
summary in  bristol myers squibb achieved record levels of sales  earnings and earnings per share 
worldwide sales grew to billion  an increase over domestic sales  which represent of worldwide sales  increased to billion  while international sales increased to billion 
exchange rate fluctuations had an unfavorable effect of on worldwide sales and on international sales 
sales growth resulted from a increase due to volume with no changes overall from pricing activity 
in  significant contributions to the company s sales growth were made by the company s most important products  many of which experienced double and even triple digit sales growth on a worldwide basis 
earnings before income taxes increased to  million in  net earnings increased to  million  basic earnings per share increased to and diluted earnings per share increased to 
net earnings and basic earnings per share have increased at compound annual growth rates of and  respectively  over the past years 
bristol myers squibb s financial position remains strong 
at december   the company held billion in cash  time deposits and marketable securities 
cash provided by operating activities totaled billion and continued to be the primary source of funding to finance dividend distributions of billion and treasury stock repurchases of billion 
dividends per common share were in  increasing from per share paid in the company s payout ratio  calculated as dividends per common share over basic earnings per common share  were  and  in  and  respectively  excluding the special charge and provision for restructuring 
in december  the company announced another dividend increase  the twenty sixth consecutive year that dividends have increased 
the indicated annual payment is per share 
bristol myers squibb s strong financial position is evidenced further by its triple a credit rating from both moody s and standard poor s  making bristol myers squibb one of only seven us companies with this distinction 
in  bristol myers squibb established its long term strategic objective to be the number one company in earnings per share growth within its competitive universe 
to achieve this objective  the company is making strategic investments behind a number of high priority projects 
the company s top priority project is to become the most productive  respected and innovative pharmaceutical research and development organization in the world 
other high priority projects focus on high growth products in fast growing markets  including pravachol  taxol r paclitaxel  glucophage and herbal essences  as well as enhancing the balanced strength of its core businesses 
during  increases were made in advertising and promotion expenditures  sales force personnel and research and development facilities and personnel to help ensure the success of these high priority projects 
total equity market capitalization was billion as of december   a increase over last year 
total return to stockholders  share price appreciation together with reinvested dividends  was for  which compares favorably to the return of the standard poor s index 
employment levels at december increased to  from  at december  with increases in the pharmaceutical sales force and increases due to acquisitions 
during the year  the company made a number of strategic acquisitions 
in january  the company completed the acquisition of redmond products  inc  a leading hair care manufacturer in the united states which markets well known products including aussie mega shampoo  aussie minute miracle conditioner and aussie sprunch spray  among others 
in latin america  the company acquired abeefe sa  peru s largest pharmaceutical manufacturer and marketer of a broad range of prescription and nonprescription anti infective  respiratory  anti inflammatory and dermatological products  choco milk  mexico s leading milk based nutritional supplement  and sal de uvas picot  a leading effervescent antacid product 
net sales and earnings worldwide sales increased in to billion  compared with increases of and in and  respectively 
the consolidated sales growth resulted from a increase due to volume  a decrease due to unfavorable foreign exchange rate fluctuations and no changes overall from pricing activity 
in  the increase in sales reflected an increase due to volume  a decrease due to unfavorable foreign exchange rate fluctuations and no changes overall from pricing activity 
in  the increase in sales reflected a increase due to volume  while price increases and exchange rate fluctuations each contributed to growth on a worldwide basis 
domestic sales increased in  and in both and  while international sales increased in  in and in in general  the businesses of the company s industry segments are not seasonal 
net earnings and basic earnings per share in increased to  million and to per share from  million and per share in net earnings and basic earnings per share were  million and per share  million and per share excluding the provision for restructuring and special charge 
diluted earnings per share in  and were  and  respectively 
net earnings margins increased to in from in both and  excluding the charges 
the effective income tax rate on earnings before income taxes was in compared to and in and  respectively 
excluding the special charge and provision for restructuring  the effective income tax rate on earnings before income taxes was in the lower effective income tax rate compared to and resulted from increased income in lower tax rate jurisdictions 
as described in the notes to the financial statements  in the fourth quarter of  the company divested linvatec corporation  its arthroscopy and surgical powered instrument business  for million  resulting in a gain of million before taxes  million after taxes 
at the same time  the company recorded a provision for restructuring of million before taxes  million after taxes 
the provision for restructuring primarily relates to the consolidation of plants and facilities and related employee termination costs 
in the fourth quarter of  the company recorded a special charge to earnings of million before taxes  million after taxes  or 
per common share  basic and diluted see note contingencies  as well as a provision for restructuring of million before taxes  million after taxes 
expenses total costs and expenses as a percentage of sales were in compared with in both and  excluding the special charge and provision for restructuring 
as a percentage of sales  cost of products sold increased to in from in  principally due to incremental low margin oncology therapeutic network sales  partially offset by increased sales of higher margin promoted pharmaceutical products 
in  cost of products sold as a percentage of sales remained relatively unchanged at compared to in excluding acquisitions  cost of products sold as a percentage of sales decreased to in due to a favorable product mix and manufacturing efficiencies 
advertising and promotion expenses in support of new and existing products increased to  million in from  million in  and as a percentage of sales  increased to from  principally due to increased spending on direct to consumer campaigns for several pharmaceutical products as well as incremental advertising support of beauty care products 
in  advertising and promotion expenses increased from levels primarily due to incremental spending in the pharmaceuticals and beauty care segments  supporting direct to consumer campaigns and new product launches  respectively 
marketing  selling and administrative expenses increased to  million in from  million in  and as a percentage of sales  decreased to in from in and in as a direct result of the company s productivity programs and higher sales volumes 
the company s investment in research and development totaled  million in  an increase of over  and as a percentage of sales  decreased to in from in this spending level reflects the company s commitment to research over a broad range of therapeutic areas and clinical development in support of new products 
the company acquired a new research facility in hopewell  nj  and announced its intention to hire  additional scientists over the next several years 
over the past years  research and development expenses have increased at a compound annual growth rate of 
in  research and development spending dedicated to the research and development of pharmaceutical products was of pharmaceutical sales compared to and in and  respectively 
during  and  the company entered into a number of research alliances  licensing agreements and biotechnology collaborations 
these agreements are providing important new products as well as early stage compounds for further development and new processes that will help the company screen for new drugs more effectively 
business segments all five of the company s business segments pharmaceuticals  consumer medicines  nutritionals  medical devices and beauty care reported sales increases  excluding foreign exchange  during the year 
by the end of  bristol myers squibb had products with more than million in annual sales  of which had more than million in annual sales 
sales in the pharmaceuticals segment  which is the company s largest segment at of total company  increased to  million in sales growth resulted from a increase in volume and a increase in selling prices  offset by a decrease due to the unfavorable effect of foreign exchange rate fluctuations 
domestic sales increased and international sales increased  excluding foreign exchange  primarily due to volume growth 
sales of pravachol  a cholesterol lowering agent  and the company s largest selling product  were billion  an increase of 
domestic sales increased to million 
results of the long term intervention with pravastatin in ischaemic disease lipid trial showed pravachol treatment reduced consequences of coronary heart disease  including heart attack  stroke and death  by to 
sales of monopril  a second generation angiotensin converting enzyme ace inhibitor with once a day dosing  increased to million  with strong growth in both domestic and international markets 
the company and sanofi sa received sa marketing clearance from the us food and drug administration fda for irbesartan and clopidogrel 
irbesartan  sold as avapro in the united states  is an angiotensin ii receptor blocker for the treatment of hypertension  and clopidogrel  to be sold as plavix in the united states  is a platelet inhibitor for the reduction of stroke and heart attack in patients with atherosclerosis 
avapro was launched in the united states during the fourth quarter  and plavix is planned to launch in early sales of cardiovascular drugs  the largest product group in the segment  increased to  million 
due to the loss of patent exclusivity in several european countries in the first quarter of  and in the united states in february  sales of captopril  an ace inhibitor sold primarily under the trademark capoten  declined million to million 
excluding capoten sales  cardiovascular drugs increased 
sales of anti cancer drugs increased to  million 
sales of taxol  the company s leading anti cancer agent  increased to million 
in june and september  the company was granted use patents in the united states covering specific dosage regimes for taxol  and in august  the fda cleared taxol for use in second line treatment of aids related kaposi s sarcoma 
sales of paraplatin  which is used in combination therapy for the treatment of ovarian cancer  increased 
sales in the oncology therapeutics network otn  a specialty distributor of anti cancer medicines and related products  acquired in october  were million 
anti infective drug sales were  million  an increase of over the prior year 
strong growth was recorded for zerit and videx  the company s two antiretroviral agents 
sales of zerit  the company s fastest growing product  increased by million  or to million  while sales of videx grew to million 
in december  zerit became the most commonly prescribed thymidine nucleoside reverse transcriptase inhibitor in hiv therapy in the united states  surpassing azt 
in august  zerit received approval from the european union for use in combination therapy for first line treatment of hiv  and in january  a new oral solution of zerit  representing a significant addition to the limited therapeutic options available to treat hiv infected infants and children  was introduced 
sales of cefzil  an oral cephalosporin used in the treatment of respiratory infections  and maxipime  a fourth generation injectable cephalosporin  also contributed to the growth of anti infectives 
sales of central nervous system drugs increased to million  due to the strong growth of buspar  the company s novel anti anxiety agent  and serzone  an antidepressant that offers a low incidence of side effects 
sales of buspar increased to million  while sales of serzone increased to million 
in may  studies presented at an american psychiatric association meeting demonstrated that serzone increased sleep efficiency in people suffering from depression 
glucophage  an oral medication for type non insulin dependent diabetes continued to experience strong growth  with sales increasing to million 
the company has sponsored a public awareness program that offers information to physicians and their patients on the proper management of type diabetes  a serious undertreated medical condition that afflicts more than million americans 
glucophage is the leading branded product in the united states for this disease 
in  pharmaceuticals segment sales increased over levels 
increases in sales of pravachol  taxol  paraplatin  zerit  monopril  buspar  cefzil  glucophage  serzone and videx were partially offset by decreases in sales of capoten  due to the loss of patent exclusivity  duricef  questran  vepesid and isovue 
the margin on earnings before taxes decreased to in from in primarily due to increased investment in advertising and promotion expenses in support of high priority products  and lower margin sales for otn 
in  the margin on earnings before taxes increased to from in due to a decrease  as a percentage of sales  in research and development spending 
sales in the consumer medicines segment increased to  million  reflecting a increase due to volume  a decrease due to the unfavorable effect of foreign exchange rate fluctuations and a decrease in selling prices 
international sales increased excluding the unfavorable effect of foreign exchange  while domestic sales increased 
sales of analgesic products increased excluding the effect of foreign exchange  due to volume growth from efferalgan and aspirine upsa from the upsa group  as well as domestic growth of excedrin 
in january  the company received clearance from the fda to market excedrin migraine  the first and only medication for migraine headache pain available to consumers without a prescription 
the sea breeze and keri lines of skin care products also performed well  with strong growth in the japanese marketplace 
vagistat  the first and only one dose over the counter medication for vaginal yeast infections  was introduced in april in  worldwide sales of consumer medicines increased from levels  an increase of  excluding foreign exchange  primarily due to increased sales of excedrin  bufferin and analgesics from the upsa group including efferalgan  dafalgan and aspirine upsa 
the margin on earnings before taxes improved to in  from in and in  as a result of efficiency gains due to productivity programs 
sales in the nutritionals segment increased to  million  reflecting a increase due to volume  a decrease due to the unfavorable effect of foreign exchange rate fluctuations and a decrease in selling prices 
international sales increased excluding the unfavorable effect of foreign exchange  while domestic sales increased 
mead johnson continues to increase its worldwide and us leadership position in the infant formula market 
total infant formula sales increased due to growth of nutramigen  lactofree and prosobee special infant formulas 
sales of enfamil  the company s largest selling infant formula  decreased to million worldwide  while increasing internationally to million  excluding foreign exchange 
boost and sustacal adult nutritional beverages  and alacta nf  a nutritious beverage for preschool age children sold outside the us  also contributed to sales growth 
in  worldwide sales of nutritionals increased from levels  primarily due to increased sales of infant formulas  including enfamil  and adult consumer nutritionals 
the margin on earnings before taxes improved to in  from in and in  primarily due to higher sales volumes  improved manufacturing efficiencies and gains due to productivity programs 
in the medical devices segment  sales of  million reflected a decrease from prior year levels 
volume gains of were achieved  while sales were impacted by a decrease due to changes in selling prices and a decrease due to the effect of foreign exchange 
international sales remained constant excluding the effect of foreign exchange  sales increased  while domestic sales decreased 
the company s convatec division is the worldwide market share leader in ostomy and advanced wound care products 
sales of ostomy and wound care products increased and  respectively  excluding foreign exchange 
the company s zimmer division continues to be the world market share leader in knee and hip replacements 
worldwide sales of knee prosthetic joint implants increased  excluding the effect of foreign exchange  led by growth of the nexgen complete knee solution 
hip replacement sales decreased  excluding the effect of foreign exchange 
zimmer is restructuring to focus on its core businesses of orthopaedic implants and fracture fixation devices 
as discussed in the notes to the financial statements  the company completed the sale of linvatec corporation  its arthroscopy and surgical powered instruments business  in december also  as part of its restructuring  zimmer announced a reduction in its domestic work force  as well as a restructuring of its european business 
in  worldwide sales of medical devices declined by million and  although excluding foreign exchange  remained at levels 
in  medical device sales increased as a result of increased sales of knee implants  and ostomy and wound care products 
excluding the acquisition of calgon vestal laboratories  and a divestiture in  sales increased in the margin on earnings before taxes in the medical devices segment decreased to in  from in and in  due to price decreases  lower sales volumes and incremental manufacturing costs in connection with recently introduced products 
sales in the beauty care segment increased in to  million  reflecting a increase due to volume  a increase due to pricing and a decrease due to foreign exchange rate fluctuations 
excluding the effect of foreign exchange  international sales increased over  while domestic sales increased 
the company s clairol division is the number one hair products company in the united states and continues to maintain its market share leadership in us haircolorings 
sales of the company s hair care products were especially strong  increasing in  primarily due to sales of the herbal essences complete line of shampoos  conditioners  styling aids and body wash  which increased to million  aided by its launch into additional countries in sales of infusium hair care products also contributed to growth of hair care products 
in september  clairol launched daily defense  a complete line of shampoos and conditioners designed to purify and fortify hair to protect it from environmental and styling stresses 
also in september  the company s matrix essentials division launched vital nutrients  an innovative hair care line that provides micro nutrients  daily protection and internal moisture balance 
haircoloring product sales increased  benefiting from the continued success of nice n easy  natural instincts  salon haircolorings and hydrience  which increased following its launch into international markets 
in  sales in the beauty care segment increased from levels  primarily due to increased sales of haircoloring  hair and skin care products 
the margin on earnings before taxes in was compared to in  and increased from in primarily due to higher volumes and productivity programs  offset by the cost of new product introductions and other spending programs 
geographic areas bristol myers squibb products are available in virtually every country in the world  its largest markets are the united states  france  japan  germany and canada 
sales in the us  net of inter area sales  increased in sales in the pharmaceuticals  beauty care and nutritionals segments  comprised  and  respectively  of the region s sales 
products with strong growth in the region included pravachol  glucophage  zerit  herbal essences  taxol  buspar  paraplatin  nutramigen  boost and incremental sales from the otn acquisition 
the margin on earnings before taxes decreased to in from in primarily due to increases  as a percentage of sales  in cost of products sold and advertising and promotion expenses 
in  sales in the us increased  net of inter area sales  primarily due to anti cancer and anti infective drugs from the pharmaceuticals segment  infant formulas from the nutritionals segment and haircoloring and hair care products from the beauty care segment 
strong sales increases were achieved despite a decline in sales of capoten 
the margin on earnings before taxes increased to in from in sales in europe  mid east and africa  net of inter area sales  increased excluding foreign exchange 
pharmaceuticals and consumer medicines  which comprised nearly of sales in the region  increased and  respectively  excluding foreign exchange 
products with strong growth in the region included zerit  pravachol  taxol  maxipime  efferalgan  plusssz  a vitamin enriched effervescent drink  and the introductions of herbal essences and hydrience 
increases in sales of these products were partially offset by decreases in sales of capoten due to the loss of exclusivity in several european countries in early the margin on earnings before taxes increased to in from in primarily due to manufacturing efficiencies as a result of the company s productivity programs 
in  sales in europe  mid east and africa  net of inter area sales  increased excluding foreign exchange  due to strong sales growth of products from the pharmaceuticals segment including anti cancer and antiretroviral drugs  which were partially offset by decreases in sales of capoten and penicillins and from the medical devices segment  including ostomy and wound care products 
in the nutritionals segment  sales of plusssz and vitamins from the acquisition of pharmavit  as well as analgesic products in the consumer medicines segment  contributed to sales growth in the region 
the margin on earnings before taxes decreased to in from in sales in other western hemisphere countries  net of inter area sales  increased in excluding foreign exchange 
pharmaceuticals  which comprised nearly of the region s sales  increased 
products with strong growth included pravachol  videx  zerit  taxol  introductory sales of hydrience and herbal essences  and sales from the acquisitions of choco milk and sal de uvas picot 
the margin on earnings before taxes increased to in from in reflecting improved gross margins due to manufacturing efficiencies 
in  sales in other western hemisphere countries increased excluding foreign exchange  due to increased sales of cardiovascular  anti cancer and anti infective drugs from the pharmaceuticals segment  infant formulas from the nutritionals segment  and haircoloring and hair care products from the beauty care segment 
sales of pharmaceutical products from the acquisition of argentia sa also contributed to sales growth in the region 
the margin on earnings before taxes decreased to in from in sales in the pacific region increased  net of inter area sales  excluding foreign exchange in pharmaceuticals and nutritionals comprised and  respectively  of the region s sales 
products with strong growth included pravachol  sea breeze  zerit  taxol  keri products  alacta nf  enfamil and the launch of herbal essences 
the margin on earnings before taxes decreased to in from in due to increases  as a percentage of sales  in cost of products sold and sales force expenses 
in  sales in the pacific region  net of inter area sales  increased excluding foreign exchange  as a result of increased sales from analgesics  infant formulas  school age nutritional beverages  skin care  anti infective and cardiovascular drugs 
the margin on earnings before taxes decreased to in from in  primarily as a result of increases  as a percentage of sales  in advertising and promotion expenditures in support of new and existing products 
financial position cash and cash equivalents  time deposits and marketable securities totaled billion at december   compared to billion at both december  and working capital was billion at december   compared to billion and billion at december  and  respectively 
cash and cash equivalents  time deposits and marketable securities  and the conversion of other working capital items are expected to fund near term operations of the company 
in august  the company issued million principal amount of debentures due august   and in november  the company issued million principal amount of debentures due november  proceeds from the sale of these securities have been used for general corporate purposes  including working capital  capital expenditures  stock repurchase programs  repayment or refinancing of borrowings  and acquisitions 
the company is exposed to market risk  including changes in currency exchange rates and interest rates 
to reduce financial risks  the company enters into certain derivative financial instruments where available on a cost effective basis to hedge its underlying economic exposure 
these instruments are also managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets 
it is the company s policy to hedge underlying economic exposures to reduce foreign exchange and interest rate risk 
derivative financial instruments are not used for trading purposes 
gains and losses on hedging transactions are offset by gains and losses on the underlying exposures being hedged 
foreign exchange option contracts and  to a lesser extent  forward contracts  are used to hedge anticipated transactions 
the company s primary foreign currency exposures in relation to the us dollar are the french franc  deutsche mark  spanish peseta and japanese yen 
the table below summarizes the company s outstanding foreign exchange option contracts as of december  the fair value of option contracts  which will change over time  is estimated based on forward currency rates and other relevant market factors 
the fair value of option contracts should be viewed in relation to the fair value of the underlying hedged transactions and the overall reduction in exposure to adverse fluctuations in foreign currency exchange rates 
dollars in millions weighted average notional carrying fair strike price amount value value maturity option contracts purchased right to sell french franc ff deutsche mark dm spanish peseta pts other currencies various right to buy japanese yen y japanese yen for deutsche marks dm other currencies various the company maintains cash and cash equivalents  time deposits and marketable securities with various financial institutions 
these financial institutions are located primarily in the us  puerto rico and ireland  and company policy is designed to limit exposure to any one financial institution 
cash and cash equivalents  time deposits and marketable securities at december  were denominated primarily in us dollar instruments with near term maturities 
the average interest yield on cash and cash equivalents was at december  while interest yields on time deposits and marketable securities averaged at december  short term borrowings and long term debt at december  are denominated primarily in us dollars but also include french franc short term borrowings due to banks of million and japanese yen long term debt of million 
disclosures related to short term borrowings and long term debt are included in the notes to the financial statements 
internally generated cash provided by operations was billion in  billion in and billion in cash provided by operations continued to be the company s primary source of funds to finance operating needs and expenditures for new plants and equipment 
as part of the company s ongoing commitment to improve plant efficiency and maintain superior research facilities  the company has invested nearly billion in capital expansion over the past three years 
cash provided by operations was also used to pay dividends of over billion over the past three years  to fund acquisitions at a cost of million over the last three years  and to finance the share repurchase program 
the company s share repurchase program authorizes the purchase of common stock from time to time in the open market or through private transactions as market conditions permit 
during  the company purchased million shares of common stock at a cost of  million  bringing the total shares acquired since the program s inception to million 
during the past three years  the company has repurchased million shares at a cost of billion 
return on stockholder s equity was in  in and in  excluding the special charge and the provision for restructuring 
the company will adopt recently issued statement of financial accounting standards no 
 employers disclosures about pensions and other postretirement benefits  in this statement does not change the measurement or the recognition of pension and postretirement expenses 
it eliminates certain current disclosures  and requires additional disclosures or changes on the benefit obligation and fair value of plan assets 
subsequent to year end  the company entered into two revolving credit facility agreements totaling million 
they are available for use as needed for general corporate purposes 
the company has reviewed its information systems for year compliance and has initiated plans to remedy any deficiencies in a timely manner 
as a result of the review and action plan  the company believes the cost of such remedial corrective actions are not material to the company s financial position  results of operations or cash flows 

